ESR1 and breast cancer: To evaluate the role of 14-3-3ζ in GR+ TNBC, we probed 14-3-3ζ mRNA expression levels across breast cancer subtypes in the TCGA dataset and stratified patients based on the expression levels of ER, PR and HER2 receptors as determined by clinical immunohistochemistry analyses of primary tumors.